CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.25BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8170xvs all stocks
52-Week Change
234.83%vs all stocks
Market Capitalization
1.25BUSDvs all stocks (USD)
Enterprise Value
1.02BUSDvs all stocks (USD)
Forward P/E
-15.07xvs Biotechnology peers
Price to Book (MRQ)
4.99xvs Biotechnology peers
Enterprise to EBITDA
-21.31xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-19.16%vs Biotechnology peers
Return on Equity (TTM)
-30.46%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-47.81MUSDvs all stocks (USD)
Net Income (TTM)
-44.17MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-34.91MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-22.57MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-42.97MUSDvs all stocks (USD)
Pre-tax Income
-15.28MUSDFY2025 · Dec 31, 2025Net Income
-15.28MUSDFY2025 · Dec 31, 2025EBIT
-42.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-70.01MUSDFY2025 · Dec 31, 2025Research & Development
33.72MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.50MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-9.97MUSDFY2025 · Dec 31, 2025Free Cash Flow
-10.14MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.58MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
105.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
38.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-91.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-70.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-174.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-91.75MUSDFY2025 · Dec 31, 2025Sale of Investments
84.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
84.09MSharesUpdated Jul 18, 2026Float Shares
72.76MSharesUpdated Jul 18, 2026Shares Short
18.82MSharesUpdated Jul 18, 2026Short Ratio
13.43daysvs all stocks
Short % of Shares Outstanding
25.44%vs all stocks
% Held by Insiders
3.51%vs all stocks
% Held by Institutions
85.57%vs all stocks
Total Cash (MRQ)
236.71MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.81USDUpdated Jul 18, 2026Total Debt (MRQ)
834.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0035xvs Biotechnology peers
Current Ratio (MRQ)
19.81xvs Biotechnology peers
Book Value per Share (MRQ)
2.86USDUpdated Jul 18, 2026Total Assets
71.12MUSDvs all stocks (USD)
Total Current Assets
58.21MUSDFY2025 · Dec 31, 2025Total Liabilities
9.91MUSDFY2025 · Dec 31, 2025Total Non-current Assets
12.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
534.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
52.17MUSDFY2025 · Dec 31, 2025Accounts Receivable
37.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.49MUSDFY2025 · Dec 31, 2025Short-term Debt
403.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
238.00KUSDFY2025 · Dec 31, 2025Long-term Debt
534.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-412.29MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
61.20MUSDvs all stocks (USD)
52-Week Low
3.96USDUpdated Jul 18, 202652-Week High
26.95USDUpdated Jul 18, 202652-Week Change
234.83%vs all stocks
Beta
0.8170xvs all stocks
50-Day MA
13.47USDUpdated Jul 18, 2026200-Day MA
12.57USDUpdated Jul 18, 2026Avg 10-Day Volume
1.27MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.36MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.5500USDUpdated Jul 18, 2026Other Income / Expense
25.18MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.25B, above the global median of $1.15BNotable
Market cap (USD): 1,252,947,317Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow